Genelux Corporation is a late clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat solid tumors. The company's lead product candidate, Olvi-Vec, is a modified strain of the vaccinia virus intended to selectively kill tumor cells and stimulate immune responses.
Description via Wikipedia
Some research tools need a free Smallfolk account or a Smallfolk Pro plan.